Project Grant HT94252510262
Award Date
5/15/25
Completion Date
5/14/27
Dollars Obligated
$427K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Oklahoma City, OK 73104, USA
Similar Awards
The University of Oklahoma Health Sciences Center was awarded an $864,781 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from April 1, 2023 to March 31, 2026 targeting DCLK1-driven chemoresistance in ovarian cancer. The goal aligns with the Military Medical Research and Development program's focus on innovative medical solutions for Service Members and the public through...
The University of Oklahoma Health Sciences Center was awarded a $1,144,000 federal Project Grant under the Military Medical Research and Development program (CFDA 12.420) by the Defense Health Agency. The grant, awarded on May 1, 2025, will fund research focused on developing a novel drug therapy that targets the ORP4 protein as a precision treatment for ovarian cancer. The research aims to transform healthcare for military service members and the broader public by investigating innovative...
The University of Oklahoma Health Sciences Center was awarded a $541,837 federal Project Grant under the Military Medical Research and Development program (CFDA 12.420), administered by the Defense Health Agency. The grant, awarded on May 1, 2025, will fund research to develop a drug targeting the ORP4 protein as a precision treatment for ovarian cancer. The research aims to transform healthcare for military service members and the general public by investigating innovative approaches to disease...
The University of Oklahoma (OU) was awarded a $1,051,250 Project Grant from the Defense Health Agency to conduct research on the re-expression of miR-195 as a therapeutic strategy for chemoresistant ovarian cancer. This research falls under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform health care for service members and the American public. The project is scheduled to run from August 15, 2023, to August 14, 2027. As a public...
This federal Project Grant award in the amount of $1,439,093.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of New Mexico Health Sciences Center (UNM HSC). The grant will support advancing clinical research on ovarian cancer over a performance period from June 1, 2024 to May 31, 2028. As part of this award, UNM HSC will leverage its expertise in cancer research, genomics, and clinical trials to conduct...
The University of Oklahoma's Health Sciences Center Division was awarded a $717,750 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to investigate one-carbon metabolic alterations to target pancreatic cancer cachexia. The research effort aims to develop new treatments and improve patient care for this condition, which is a major concern for service members and veterans. The three-year project will be conducted in Oklahoma City,...
The Defense Health Agency has awarded a $968,400 Project Grant to Mayo Clinic to develop a personalized approach to treating drug-resistant ovarian cancer. The grant, which began on June 1, 2024, and will run through May 31, 2028, is funded under the Military Medical Research and Development program (CFDA 12.420). This program supports biomedical research to improve the health and care of military service members, veterans, and their families. Through this award, Mayo Clinic will leverage its...
The University of Nebraska Medical Center (UNMC) was awarded a $927,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research titled "TARGETING FGFR4 SIGNALING TO OVERCOME CHEMORESISTANCE IN OVARIAN CANCER". The grant has an award date of July 1, 2024 and an ultimate completion date of June 30, 2028. UNMC, a leading institution in health sciences education, innovative research, and patient care, will...
This federal Project Grant award, in the amount of $915,000.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award is intended to "IMPROVE TARGETED OVARIAN CANCER THERAPY USING THE NOVEL NOTCH PATHWAY INHIBITOR AURANOFIN" at the University of New Mexico Health Sciences Center (UNM HSC) over the period of July 1, 2024 to June 30, 2027. UNM HSC, a leading academic medical center and health sciences institution,...
This $125,050 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by the University of New South Wales (UNSW) to investigate the use of UDP-glucose in inducing ovarian cancer cell death and promoting antitumor immunity. The research aims to advance the understanding of therapeutic approaches for ovarian cancer, with the ultimate completion date of June 30, 2026. As a leading Australian research...